Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

BioAge Labs, Inc.

BIOA · Nasdaq · CIK 0001709941 · Healthcare · Drug Manufacturers—Specialty & Generic

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

11 Form 4 transaction lines observed in the same window
2 sales · 9 option, withholding, award, gift or other lines

Last qualifying purchase2024-10-03 · Pande Vijay Satyanand · $503.6K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesLow
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Barton ShanePrincipal Accounting Officer
○▼○▼
GOLDSTEIN DOV A MDChief Financial Officer
○
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-10-03 · Pande Vijay Satyanand.

Recent Form 4 activity

0Purchases
13Sales
23Other Form 4 lines
13SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING2 sale line(s) · context only
OTHER9 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-40.2%
3M
-78.3%
6M
-73.8%
12M
-14.9%

Volatility & liquidity

Volatility
105.3%
Beta
—
Avg daily value
USD 4.6M

Valuation

Market cap
USD 222.1M
P/E
—

Fundamentals

Profit margin
-896.1%
ROE
-29.6%
Industry
Drug Manufacturers—Specialty & Generic

Market data

Price data up to: 2026-10-18 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
3,274,379
Previous report
3,073,976
Avg daily volume
830,478
Days to cover
3.9

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2024-10-03Pande Vijay SatyanandPurchase (P)Common Stock25,306USD 19.90USD 503,589SEC filing ↗
2024-10-02Pande Vijay SatyanandPurchase (P)Common Stock67,096USD 19.73USD 1,323,804SEC filing ↗
2024-10-01Pande Vijay SatyanandPurchase (P)Common Stock126,793USD 19.73USD 2,501,626SEC filing ↗
2024-09-27Hemrajani RekhaPurchase (P)Common Stock3,000USD 18.00USD 54,000SEC filing ↗
2024-09-27Barton ShanePurchase (P)Common Stock2,632USD 18.00USD 47,376SEC filing ↗
2024-09-27Chen Bihua; Cormorant Asset Management, LP; Cormorant Private Healthcare Fund IV LP; Cormorant Private Healthcare Fund V LPPurchase (P)Common Stock450,000USD 18.00USD 8,100,000SEC filing ↗
2024-09-27Pande Vijay SatyanandPurchase (P)Common Stock900,000USD 18.00USD 16,200,000SEC filing ↗
2024-09-27HEALY JAMESPurchase (P)Common Stock666,665USD 18.00USD 11,999,970SEC filing ↗
2024-09-27ENRIGHT PATRICK GPurchase (P)Common Stock400,000USD 18.00USD 7,200,000SEC filing ↗

Form 4 evidence

36 transaction lines in the latest 365-day window; 56 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-30Barton ShaneSale (S)Common Stock20,216USD 25.19USD 509,241SEC filing ↗
2026-06-30Barton ShaneOption exercise / conversion (M)Common Stock20,216USD 6.53USD 132,017SEC filing ↗
2026-06-29Barton ShaneSale (S)Common Stock42,350USD 25.21USD 1,067,644SEC filing ↗
Show recent Form 4 evidence (23 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-30Barton ShaneSale (S)Common Stock20,216USD 25.19USD 509,241SEC filing ↗
2026-06-30Barton ShaneOption exercise / conversion (M)Common Stock20,216USD 6.53USD 132,017SEC filing ↗
2026-06-29Barton ShaneSale (S)Common Stock42,350USD 25.21USD 1,067,644SEC filing ↗
2026-06-29Barton ShaneOption exercise / conversion (M)Common Stock39,718USD 6.61USD 262,542SEC filing ↗
2026-04-23GOLDSTEIN DOV A MDOption exercise / conversion (M)Common Stock3,542USD 4.38USD 15,514SEC filing ↗
2026-04-01RUBIN PAUL DSale (S)Common Stock8,820USD 17.81USD 157,084SEC filing ↗
2026-04-01RUBIN PAUL DOption exercise / conversion (M)Common Stock8,820USD 5.05USD 44,572SEC filing ↗
2026-03-02RUBIN PAUL DSale (S)Common Stock7,433USD 20.30USD 150,890SEC filing ↗
2026-03-02RUBIN PAUL DOption exercise / conversion (M)Common Stock7,433USD 4.77USD 35,470SEC filing ↗
2026-03-01GOLDSTEIN DOV A MDOption exercise / conversion (M)Common Stock3,542USD 4.38USD 15,514SEC filing ↗
2026-02-02RUBIN PAUL DSale (S)Common Stock7,433USD 18.75USD 139,369SEC filing ↗
2026-02-02RUBIN PAUL DOption exercise / conversion (M)Common Stock7,433USD 4.77USD 35,470SEC filing ↗
2026-02-01GOLDSTEIN DOV A MDOption exercise / conversion (M)Common Stock3,541USD 4.38USD 15,510SEC filing ↗
2026-01-16GOLDSTEIN DOV A MDOption exercise / conversion (M)Common Stock3,542USD 4.38USD 15,514SEC filing ↗
2026-01-13GOLDSTEIN DOV A MDSale (S)Common Stock27,000USD 19.70USD 531,844SEC filing ↗
2026-01-13GOLDSTEIN DOV A MDOption exercise / conversion (M)Common Stock27,000USD 8.39USD 226,530SEC filing ↗
2026-01-13Fortney KristenSale (S)Common Stock233,107USD 18.12USD 4,223,899SEC filing ↗
2026-01-02RUBIN PAUL DSale (S)Common Stock7,433USD 12.85USD 95,514SEC filing ↗
2026-01-02RUBIN PAUL DOption exercise / conversion (M)Common Stock7,433USD 4.77USD 35,470SEC filing ↗
2025-12-09RUBIN PAUL DSale (S)Common Stock18,000USD 12.00USD 216,000SEC filing ↗
2025-12-09RUBIN PAUL DOption exercise / conversion (M)Common Stock18,000USD 6.57USD 118,260SEC filing ↗
2025-12-04RUBIN PAUL DSale (S)Common Stock68,897USD 10.19USD 702,060SEC filing ↗
2025-12-04RUBIN PAUL DOption exercise / conversion (M)Common Stock68,897USD 4.11USD 283,167SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerBIOA
CIK0001709941
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history56 transaction lines from 2024-09-27 to 2026-06-30
13 P purchase lines · 13 S sale lines · 30 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.